| 0.395 0.012 (3.13%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.58 | 1-year : | 0.68 |
| Resists | First : | 0.5 | Second : | 0.58 |
| Pivot price | 0.36 |
|||
| Supports | First : | 0.33 |
Second : | 0.23 |
| MAs | MA(5) : | 0.36 |
MA(20) : | 0.35 |
| MA(100) : | 0.34  |
MA(250) : | 0.72 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 53 |
D(3) : | 47.4 |
| RSI | RSI(14): 59.8 |
|||
| 52-week | High : | 1.4 | Low : | 0.18 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ KZIA ] has closed below upper band by 33.1%. Bollinger Bands are 2.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.41 - 0.41 | 0.41 - 0.41 |
| Low: | 0.36 - 0.36 | 0.36 - 0.36 |
| Close: | 0.39 - 0.39 | 0.39 - 0.4 |
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Thu, 21 Mar 2024
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases - Newswise
Wed, 13 Mar 2024
Kazia announces presentation of new data at AACR Annual Meeting - PR Newswire
Wed, 21 Feb 2024
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint - PR Newswire
Sun, 18 Feb 2024
Biotech Ventures: Capitalize on Innovation - DataDrivenInvestor
Thu, 18 Jan 2024
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS - PR Newswire
Tue, 05 Dec 2023
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -7 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 2.636e+007 (%) |
| Held by Institutions | 2.19e+008 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.73 |
| Profit Margin | 0 % |
| Operating Margin | -148 % |
| Return on Assets (ttm) | 56 % |
| Return on Equity (ttm) | 737.5 % |
| Qtrly Rev. Growth | -186.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.98 |
| Qtrly Earnings Growth | -1.752e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -0.55 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 259530 |
| Forward Dividend | 765130 |
| Dividend Yield | 65703800% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|